ArticleOrthopaedic journal of sports medicine2026
Conditional Survivorship of Osteochondral Allograft Transplantation in the Knee.
Article in Orthopaedic journal of sports medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteochondral allograft (OCA) transplantation has demonstrated reliable long-term outcomes in treating chondral and osteochondral lesions of the knee. Although several pre- and intraoperative factors associated with graft failure have been identified, the temporal distribution of graft failures after OCA transplantation has not been described. Purpose: To evaluate the timing and rate of graft failure after knee OCA transplantation and to report conditional survivorship (CS) to inform postoperative patient counseling. Study Design: Case series; Level of evidence, 4. Methods: We identified 288 knees (267 patients) that underwent OCA transplantation by a single surgeon between 1997 and 2015, with a minimum follow-up of 10 years. Graft failure was defined as any reoperation requiring removal of the allograft. Nonfailure reoperation was defined as any surgical procedure on the affected knee that did not involve graft removal. Rates of graft failure and nonfailure reoperation were estimated using piecewise linear regression applied to inverse Kaplan-Meier curves. Kaplan-Meier analysis estimated overall and 10-year CS. Results: The median patient age was 33.1 years (range, 11-68 years), and 58% were male. Overall graft survivorship was 78% at 10 years. Graft failure occurred in 64 knees (22%) at a median of 2.7 years (range, 0.3-23.6) postoperatively. Annual failure rates were 4.9% in the first 3 years postoperatively and decreased to 1.5% from 3 to 10 years. Nonfailure reoperations occurred in 48 knees, with a median of 1.5 years postoperatively, and followed a similar temporal pattern, with most occurring in the early postoperative period. CS analysis demonstrated that grafts remaining in situ at 4 years postoperatively had a 90% probability of survival to 10 years. Conclusion: OCA transplantation of the knee demonstrated an overall 10-year graft survivorship of 78%. Graft failures were not uniformly distributed over time, with the highest failure rates occurring during the early postoperative period and substantially decreasing after 3 years postoperatively to a low steady-state of 1.5% annually. This temporal pattern was also noted with nonfailure reoperations, which occurred predominantly during the early postoperative period. CS analysis offers a patient-centered approach for interpreting these findings and may inform postoperative patient counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.